Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Primary CNS Lymphoma in Myasthenic on Long-term Azathioprine
J NeuroOncol 74:91-92, Finelli,P.F., 2005
Primary CNS Lymphoma Complicating Treatment of Myasthenia Gravis with Mycophenolate Mofetil
Neurol 65:639-641, Vernino,S.,et al, 2005
B Cell Lymphoma of the Brain Stem Masquerading as Myasthenia
JNNP 72:271-273, Shams,P.N.,et al, 2002
The Expanding Spectrum of Herpesvirus Infections of the Nervous System
Brain Pathol 11:440-451, Kleinschmidt-DeMasters,B.K. &Gilden,D.H., 2001
The Expanding Spectrum of Herpesvirus Infections of the Nervous System
Brain Pathology 11:440-451, Kleinschmidt-DeMasters,B.K. &Gilden,D.H., 2001
Association of Primary Central Nervous System Lymphoma with Long-Term Azathioprine Therapy for Myasthenia Gravis?
Ann Neurol 47: 682-683, Herrlinger,U.,et al, 2000
Assoc of Myasthenia Gravis with Extrathymic Hodgkin's Lymphoma:Resol of Myasth Sympt Following Antineopl Therapy
Neurol 45:1019, Abrey,L.E.&Askanas,V., 1995
Myasthenia Gravis after Botulinum Toxin Type A Injection
Turk J Neurol 22:143-144, Tekce, H.D.,et al, 2016
Clinicopathologic Conference, Inflammatory Myopathy and Myasthenia Gravis Assoc. with Thymoma
NEJM 369:764-773, Case 26-2013, 2013
Clinicopathologic Conference, Thymoma with Paraneoplastic Myasthenia Gravis, Polymyositis and Myocarditis, and Brain Stem Encephalitis
NEJM 365:2413-2422, Case 39-2011, 2011
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
Bilateral Ocular Paralysis: Analysis of 31 Inpatients
Arch Neurol 64:178-180, Keane,J.R., 2007
Thymoma in Patients with MG
Neurol 59:1844-1850, Evoli,A.,et al, 2002
Morvan's Fibrillary Chorea: A Paraneoplastic Manifestation of Thymoma
JNNP 65:857-862, Lee,E.K.,et al, 1998
Intestinal Pseudo-Obstruction, Myasthenia Gravis, and Thymoma
Neurol 47:985-987, Anderson,N.E.,et al, 1996
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Ocular Pseudomyasthenia or Ocular Myasthenia'Plus':A Warning to Clinicians
Neurol 39:1150-1154, Moorthy,G.,et al, 1989
Azathioprine Toxicity During Long-Term Immunosuppression of Generalized Myasthenia Gravis
Neurol 38:258-261, Hohlfeld,R.,et al, 1988
Acute Bilateral Ophthalmoplegia:60 Cases
Neurol 36:279-281, Keane,J.R., 1986
Myasthenia Gravis & Lymphoma, A Clinical & Immunological Assocation
JAMA 242:2096-2097, Davis,S.,et al, 1979
Neurological Problems in Endocrine Diseases
Med Clin North Am 56:1029, Dale,A., 1972
Internuclear Ophthalmoplegia, Typical & Atypical
Arch Ophthal 84:583, Cogan,D.G., 1970
Rituximab Therapy in the Treatment of Juvenile Myasthenia Gravis
Neurol 98:e2368-e2376, Molimard, A.,et al, 2022
A New Option is Approved for Patients with Myasthenia Gravis
JAMA 327:417, Voelker, R., 2022
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
International Consensus Guidance for Management of Myasthenia Gravis
Neurol 87:419-425, Sanders, D.B.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Immunosuppressant Drugs for Myasthenia Gravis
JNNP 80:5-6, Hart,I.K.,et al, 2008
Evidence Report: The Medical Treatment of Ocular Myasthenia (An Evidence-Based Review)
Neurol 68:2144-2149, Benatar,M. &Kaminski,H.J., 2007
Extrathymic Tumors in Patients With Myasthenia Gravis, A 35-Year Retrospective Study
The Neurologist 12:53-55, Wakata,N.,et al, 2006
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Ocular Myasthenia: Diagnosis, Treatment and Pathogenesis
The Neurologist 12:231-239, Kusner,L.,et al, 2006
Management of Myasthenia Gravis
Semin Neurol 24:41-48, Saperstein,D.S. &Barohn,R.J., 2004
Treatment of Refractory Myasthenia: "Rebooting" with High-Dose Cyclophosphamide
Ann Neurol 53:29-34,7, Drachman,D.B.,et al, 2003
Treatment of Autoimmune Myasthenia Gravis
Neurol 61:1652-1661, Richman,D.P. & Agius,M.A., 2003
Steroid Treatment for Myasthenia Gravis
Muscle Nerve 25:115-121, Rivner,M.H., 2002
Retrospective Analysis of the Use of Cyclosporine in Myasthenia Gravis
Neurol 55:448-450, Ciafaloni,E. et al, 2000
Course and Treatment of Myasthenia Gravis During Pregnancy
Neurol 52:447-452, Batocchi,A.P.,et al, 1999
Neuroendocrine Lung Tumors and Disorders of the Neuromuscular Junction
Neurol 52:1490-1491, Burns,T.M.,et al, 1999
A Randomized Double-Blind Trial of Prednisolone Alone or with Azathioprine in Myasthenia Gravis
Neurol 50:1778-1783, Palace,J.,et al, 1998
Successful Treatment of a Patient with Severe Refractory Myasthenia Gravis Using Mycophenolate Mofetil
Neurol 51:912-913, Hauser,R.A.,et al, 1998
Ocular Myasthenia Gravis:Response to Long Term Immunosuppressive Treatment
JNNP 62:156-162, Sommer,N.,et al, 1997